Minimally invasive catheter-based treatment options, such as TAVR (Transcatheter Aortic Valve Replacement), are offered for patients who are considered too ill to survive open-heart surgery to replace valves affected by severe stenosis.
More patients with heart valve disease may be candidates for the transcatheter aortic valve replacement (TAVR) procedure as an alternative to open-heart surgery, since the Food and Drug Administration (FDA) expanded the patient eligibility criteria. Read more.
